

**Generic Handbook (2007 Edition)**  
**List of Contents**

|   |           |
|---|-----------|
| <b>Chapter One. Introduction to US Generic Drug Market.....</b> | <b>x</b>  |
| <b>Overview .....</b>   | <b>XX</b> |
| <b>Methodology .....</b>  | <b>XX</b> |
| Time Considerations .....                                       | x         |
| Legal Disclaimer .....  | x         |
| <b>Key Terms &amp; Abbreviations .....</b>                      | <b>x</b>  |
| <br>  |           |
| <b>Chapter Two. Context of Generic Drugs in the US.....</b>     | <b>xx</b> |
| <b>Introduction.....</b>  | <b>XX</b> |
| <b>History.....</b>   | <b>XX</b> |
| <b>The US Drug Market.....</b>                                  | <b>XX</b> |
| Sales .....   | XX        |
| Prescription Volume.....  | XX        |
| <b>Sales Channels.....</b>                                      | <b>XX</b> |
| <b>Generics versus Brands .....</b>                             | <b>XX</b> |
| Brands Losing Patent Protection .....                           | XX        |
| Generic versus Brand Sales.....                                 | XX        |
| Generic versus Brand Prescription Volume .....                  | XX        |
| Generic versus Brand Market Share.....                          | XX        |
| <b>Generic versus Brand Prices.....</b>                         | <b>XX</b> |
| Sales to Volume Ratio.....                                      | XX        |
| <b>Factors Affecting Generic Entry .....</b>                    | <b>XX</b> |
| <b>Factors Affecting Generic Penetration .....</b>              | <b>XX</b> |
| <b>Substitution of Branded Prescriptions.....</b>               | <b>XX</b> |
| <br>  |           |
| <b>Chapter Three. Regulatory and Legal Environment.....</b>     | <b>xx</b> |
| <b>Key Regulatory Bodies &amp; Responsibilities .....</b>       | <b>XX</b> |
| <b>Food Drug and Cosmetics Act (FDCA) .....</b>                 | <b>XX</b> |
| <b>Public Health Service Act (PHSA) .....</b>                   | <b>XX</b> |
| <b>Regulatory Essentials of the Generic Market .....</b>        | <b>XX</b> |
| Patents .....   | XX        |
| Exclusivity.....  | XX        |
| Office of Generic Drugs.....                                    | XX        |
| Orange Book .....   | XX        |
| Patent Listings in the Orange Book.....                         | XX        |
| Drug Master Files.....  | XX        |
| Citizen Petition.....   | XX        |
| Therapeutic Equivalence Codes .....                             | XX        |
| TE Codes .....  | XX        |
| <b>Hatch-Waxman Act of 1984.....</b>                            | <b>XX</b> |

|  |           |
|--|-----------|
| ANDA versus NDA .....                      | XX        |
| The Four ANDA Paragraphs:.....             | XX        |
| 505(b)(x) – Paper NDA.....                 | XX        |
| Bolar .....                                | XX        |
| Impact of the MMA.....                     | XX        |
| When can generic enter? .....              | XX        |
| Economics of Paragraph IV .....            | XX        |
| Predicting Paragraph IV Outcomes .....     | XX        |
| Paragraph IV Filings .....                 | XX        |
| At-Risk Launches .....                     | XX        |
| Reverse Payments .....                     | XX        |
| <b>CMS, Medicare, Medicaid .....</b>       | <b>XX</b> |
| Pricing Considerations .....               | XX        |
| Best price issues .....                    | XX        |
| Medicaid.....                              | XX        |
| <b>Generic Substitution Policies .....</b> | <b>XX</b> |

## **Chapter Four.**

### **Political, Legal & Regulatory Developments.....XX**

|   |           |
|---|-----------|
| <b>Impact of New Democratic Congress.....</b> | <b>XX</b> |
| Waxman-Clinton Bill .....                     | XX        |
| Part D Price Negotiations.....                | XX        |
| Biogenerics.....                              | XX        |
| Authorized Generics.....                      | XX        |
| Pediatric Exclusivity .....                   | XX        |
| User Fees .....                               | XX        |
| <b>Anti-trust Developments .....</b>          | <b>XX</b> |
| Schering Decision .....                       | XX        |
| Impact on Out-of-Court Settlements .....      | XX        |
| Plavix Case Study.....                        | XX        |
| FTC Response .....                            | XX        |
| <b>FDA Developments .....</b>                 | <b>XX</b> |
| ANDA Approvals.....                           | XX        |
| OGD Backlog.....                              | XX        |
| Electronic ANDA Filing .....                  | XX        |
| Proposals for Expedited Approvals.....        | XX        |

### **Chapter Five. The US Generic Drug Market.....XX**

|                                      |           |
|--------------------------------------|-----------|
| <b>Introduction.....</b>             | <b>XX</b> |
| <b>Key Success Factors.....</b>      | <b>XX</b> |
| <b>Buyers.....</b>                   | <b>XX</b> |
| The Private Market.....              | XX        |
| Public Market Buyers.....            | XX        |
| Medicare.....                        | XX        |
| Impact of MMA on Generic Sector..... | XX        |
| Medicaid.....                        | XX        |
| <b>Current Market.....</b>           | <b>XX</b> |

|   |           |
|---|-----------|
| <b>Market Forecasts .....</b>                                     | <b>XX</b> |
| Generic Approval Trends .....                                     | XX        |
| Pricing and Margin Trends .....                                   | XX        |
| Penetration rates .....   | XX        |
| <b>Marketing and the distribution chain .....</b>                 | <b>XX</b> |
| Sales Channels.....   | XX        |
| PBMs.....   | XX        |
| Leading wholesalers .....   | XX        |
| Retailers.....  | XX        |
| Wal-Mart \$4 Generics .....                                       | XX        |
| <b>Customer Attitudes.....</b>                                    | <b>XX</b> |
| Physicians.....   | XX        |
| Patients .....  | XX        |
| Pharmacists.....  | XX        |
| <b>Emerging market suppliers.....</b>                             | <b>XX</b> |
| India.....  | XX        |
| China .....   | XX        |
| Eastern Europe .....  | XX        |
| <b>Mergers &amp; Acquisitions.....</b>                            | <b>XX</b> |
| <br>  |           |
| <b>Chapter Six. Major Issues Facing the Generic Industry.....</b> | <b>XX</b> |
| <br>  |           |
| <b>Authorized generics .....</b>                                  | <b>XX</b> |
| Definition and Prevalence .....                                   | XX        |
| Economic Impact.....  | XX        |
| Regulatory Attitudes / Actions .....                              | XX        |
| FDA.....  | XX        |
| FTC .....   | XX        |
| Courts .....  | XX        |
| CMS .....   | XX        |
| <b>Biogenerics.....</b>   | <b>XX</b> |
| The Need and Opportunity .....                                    | XX        |
| Background .....  | XX        |
| Definition of “Biologics” .....                                   | XX        |
| Terminology .....   | XX        |
| PHS Act.....  | XX        |
| Qualifying “sameness” .....                                       | XX        |
| Manufacturing Issues .....  | XX        |
| Possible need for trials .....                                    | XX        |
| Marketing .....   | XX        |
| Likely outcomes .....   | XX        |
| FDA Timelines.....  | XX        |
| International situation.....                                      | XX        |
| <b>Wal-Mart \$4 Generics .....</b>                                | <b>XX</b> |
| <br>  |           |
| <b>Chapter Seven. Products.....</b>                               | <b>XX</b> |
| <br>  |           |
| <b>Overview .....</b>   | <b>XX</b> |
| <b>Generic Products.....</b>                                      | <b>XX</b> |

|  |            |
|--|------------|
| Top 200 Generic Products by Retail Sales .....                           | XX         |
| Top 200 Generic Products by Retail Prescription Volume .....             | XX         |
| Prices of Top 200 Generics .....   | XXX        |
| Active Companies by Main Active Ingredient.....                          | XXX        |
| Active Companies by Precise Compound(s).....                             | XXX        |
| <b>Brand Products .....</b>  | <b>XXX</b> |
| Top 200 Branded Products (Sales & Volume).....                           | XXX        |
| Details of Leading Branded Products.....                                 | XXX        |
| Intellectual Property Status for All FDA Approved Innovative Drugs ..... | XXX        |
| Innovative Products Arranged by Generic Compound Name .....              | XXX        |
| Top 20 Generic Companies by US Retail Pharmacy Sales .....               | XXX        |
| ANDAs Awaiting Approval (as of December 2006) .....                      | XXX        |
| <b>Delivery Systems by Company .....</b>                                 | <b>XXX</b> |
| INHALATION .....   | XXX        |
| INJECTION .....  | XXX        |
| INTRAVENOUS .....  | XXX        |
| IRRIGATION.....  | XXX        |
| IV (INFUSION) .....  | XXX        |
| NASAL .....  | XXX        |
| OPHTHALMIC.....  | XXX        |
| ORAL.....  | XXX        |
| OTIC .....   | XXX        |
| RECTAL .....   | XXX        |
| TOPICAL.....   | XXX        |
| TRANSDERMAL.....   | XXX        |
| VAGINAL.....   | XXX        |

**Chapter Eight. Profiles of Top 75 US Generic Companies..... xxx**

Includes company profiles, executive names, contact information, ownership, financial information (public companies only)

Abraxis  
 Abrika  
 Actavis  
 Affordable Pharm  
 AHP  
 Akyma  
 Alharma US  
 American Regent  
 Amide  
 Andrx  
 AndrxPharma  
 Apotex  
 Armstrong  
 Aurobindo  
 Barr  
 Bausch & Lomb  
 Bedford Laboratories  
 Bergen Brunswig  
 Bertek  
 BocaPharmcal

Breckenridge  
Caraco  
Cypress  
Danbury  
Dava  
Dey Laboratories  
Dr. Reddy's  
Endo Generic  
Eon Laboratories  
Ethex  
Excellium  
Falcon  
Forest  
Fougera  
G&W Laboratories  
Glades  
GlaxoSmithKline  
Glenmark  
Global  
Greenstone  
Hercon  
Hi-Tech  
Hospira  
Interpharm  
Inwood Laboratories  
Ivax  
Ivax Laboratories  
Kremers Urban  
Lannett  
Lupin  
Major  
Mallinkrodt  
Midlothian  
Mikart  
Monarch  
Morton Grove  
Mutual  
Mylan  
Paddock  
Par  
Patriot  
Perrigo  
Pharmaceutcial Assoc  
Pharmaderm  
Pliva  
Prasco Laboratories  
Purepac  
Qualitest  
Ranbaxy  
Ranbaxy Brand  
Repacker

Rising  
River's Edge  
Roxane  
Rugby  
RxElite  
Sandoz  
Sicor  
Stada  
Store Brand Mfg  
Sunmark  
Taro USA  
Teva USA  
Three Rivers  
Triax  
Unit-Dose  
Upsher-Smith  
Upstate  
URL  
Warrick  
Watson Laboratories  
West-Ward  
Wockhardt USA  
Xanodyne  
Xttrium Laboratories  
Zydus